A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance
Qiyao Zheng, Hui Dong, Jianshan Mo, Yi Zhang, Jie Huang, Shumin Ouyang, Shuo Shi, Kai Zhu, Xinming Qu, Wenhao Hu, Peiqing Liu, Yuanxiang Wang, Xiaolei Zhang
Abstract
Our study has provided a novel STAT3 inhibitor with significant anti-tumor activities in NSCLC and suggests that combination of STAT3 inhibitor such as W2014-S with gefitinib could serve as a promising strategy to overcome EGFR-TKIs acquired resistance in NSCLC patients.
Topics & Concepts
GefitinibErlotinibCancer researchSTAT3Erlotinib HydrochlorideLung cancerCancerBiologyEpidermal growth factor receptorMedicineSignal transductionPathologyInternal medicineCell biologyLung Cancer Treatments and MutationsCytokine Signaling Pathways and InteractionsCancer Mechanisms and Therapy